Nevertheless, although no statistically significant differences in kidney or pancreas rejection rates were observed between thymoglobulin and basiliximab, our data showed a numerical trend toward higher rejection in the basiliximab group, as previously reported in other studies [ 17 , 18 ].
← all excerpts
Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation.
1
—
—